Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Stratos Wealth Advisors LLC

Stratos Wealth Advisors LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 38.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,327 shares of the medical research company's stock after selling 1,468 shares during the quarter. Stratos Wealth Advisors LLC's holdings in Thermo Fisher Scientific were worth $1,158,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its stake in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG raised its stake in Thermo Fisher Scientific by 0.3% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after purchasing an additional 461 shares during the last quarter. Proficio Capital Partners LLC raised its stake in Thermo Fisher Scientific by 32.1% in the 4th quarter. Proficio Capital Partners LLC now owns 1,466 shares of the medical research company's stock valued at $763,000 after purchasing an additional 356 shares during the last quarter. Finally, Moran Wealth Management LLC raised its stake in Thermo Fisher Scientific by 2.4% in the 4th quarter. Moran Wealth Management LLC now owns 1,089 shares of the medical research company's stock valued at $567,000 after purchasing an additional 26 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Up 1.0%

NYSE TMO traded up $4.29 on Friday, reaching $435.02. The company had a trading volume of 2,511,384 shares, compared to its average volume of 1,999,630. The firm has a 50-day moving average of $409.39 and a 200-day moving average of $476.23. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The firm has a market capitalization of $164.22 billion, a PE ratio of 25.51, a P/E/G ratio of 2.31 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same period in the prior year, the company posted $5.11 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Analysts Set New Price Targets

TMO has been the subject of a number of research analyst reports. Barclays dropped their price objective on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research note on Tuesday, June 24th. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a report on Friday. Finally, Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $600.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.